Designed multiple ligands. An emerging drug discovery paradigm.

Article Details

Citation

Morphy R, Rankovic Z

Designed multiple ligands. An emerging drug discovery paradigm.

J Med Chem. 2005 Oct 20;48(21):6523-43.

PubMed ID
16220969 [ View in PubMed
]
Abstract

Not Available

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic AcidPeroxisome proliferator-activated receptor gammaKd (nM)170N/AN/ADetails
BosutinibProto-oncogene tyrosine-protein kinase SrcIC 50 (nM)3.8N/AN/ADetails
BosutinibTyrosine-protein kinase ABL1IC 50 (nM)1.1N/AN/ADetails
CaptoprilAngiotensin-converting enzymeIC 50 (nM)23N/AN/ADetails
CelecoxibCarbonic anhydrase 2IC 50 (nM)21N/AN/ADetails
CetirizineHistamine H1 receptorKi (nM)14N/AN/ADetails
ClozapineD(2) dopamine receptorIC 50 (nM)9N/AN/ADetails
ClozapineD(4) dopamine receptorIC 50 (nM)138N/AN/ADetails
CyproheptadineHistamine H1 receptorKd (nM)5400N/AN/ADetails
DuloxetineSodium-dependent dopamine transporterKi (nM)370N/AN/ADetails
DuloxetineSodium-dependent noradrenaline transporterKi (nM)16N/AN/ADetails
DuloxetineSodium-dependent serotonin transporterKi (nM)4.6N/AN/ADetails
FluoxetineSodium-dependent serotonin transporterKi (nM)48N/AN/ADetails
ImatinibPlatelet-derived growth factor receptor betaIC 50 (nM)50N/AN/ADetails
ImatinibTyrosine-protein kinase ABL1IC 50 (nM)38N/AN/ADetails
IrbesartanType-1 angiotensin II receptorKi (nM)0.8N/AN/ADetails
LicofelonePolyunsaturated fatty acid 5-lipoxygenaseIC 50 (nM)210N/AN/ADetails
LicofeloneProstaglandin G/H synthase 2IC 50 (nM)370N/AN/ADetails
LoratadineHistamine H1 receptorIC 50 (nM)290N/AN/ADetails
MilnacipranSodium-dependent serotonin transporterIC 50 (nM)100N/AN/ADetails
Pindolol5-hydroxytryptamine receptor 1AKi (nM)110N/AN/ADetails
Roxatidine acetateHistamine H2 receptorKd (nM)251.19N/AN/ADetails
Ziprasidone5-hydroxytryptamine receptor 2AIC 50 (nM)0.42N/AN/ADetails
ZiprasidoneD(2) dopamine receptorIC 50 (nM)5N/AN/ADetails